PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcmicrBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Microbiology
 
BMC Microbiol. 2010; 10: 267.
Published online Oct 20, 2010. doi:  10.1186/1471-2180-10-267
PMCID: PMC2973968
Universal and specific quantitative detection of botulinum neurotoxin genes
Brenna J Hill,1 Janet C Skerry,2 Theresa J Smith,2 Stephen S Arnon,3 and Daniel C Douekcorresponding author1
1Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 USA
2Integrated Toxicology Division, USAMRIID, Fort Detrick, MD 21702 USA
3Infant Botulism Treatment and Prevention Program, California Department of Public Health, Richmond, CA 94804 USA
corresponding authorCorresponding author.
Brenna J Hill: brhill/at/mail.nih.gov; Janet C Skerry: janet.skerry/at/us.army.mil; Theresa J Smith: theresa.j.smith/at/us.army.mil; Stephen S Arnon: Stephen.Arnon/at/cdph.ca.gov; Daniel C Douek: ddouek/at/mail.nih.gov
Received April 20, 2010; Accepted October 20, 2010.
Background
Clostridium botulinum, an obligate anaerobic spore-forming bacterium, produces seven antigenic variants of botulinum toxin that are distinguished serologically and termed "serotypes". Botulinum toxin blocks the release of acetylcholine at neuromuscular junctions resulting in flaccid paralysis. The potential lethality of the disease warrants a fast and accurate means of diagnosing suspected instances of food contamination or human intoxication. Currently, the Food and Drug Administration (FDA)-accepted assay to detect and type botulinum neurotoxins (BoNTs) is the mouse protection bioassay. While specific and sensitive, this assay requires the use of laboratory animals, may take up to four days to achieve a diagnosis, and is unsuitable for high-throughput analysis. We report here a two-step PCR assay that identifies all toxin types, that achieves the specificity of the mouse bioassay while surpassing it in equivalent sensitivity, that has capability for high-throughput analysis, and that provides quantitative results within hours. The first step of our assay consists of a conventional PCR that detects the presence of C. botulinum regardless of the neurotoxin type. The second step uses quantitative PCR (qPCR) technology to determine the specific serotype of the neurotoxin.
Results
We assayed purified C. botulinum DNA and crude toxin preparations, as well as food and stool from healthy individuals spiked with purified BoNT DNA, and one stool sample from a case of infant botulism for the presence of the NTNH gene, which is part of the BoNT gene cluster, and for the presence of serotype-specific BoNT genes. The PCR surpassed the mouse bioassay both in specificity and sensitivity, detecting positive signals in BoNT preparations containing well below the 1 LD50 required for detection via the mouse bioassay. These results were type-specific and we were reliably able to quantify as few as 10 genomic copies.
Conclusions
While other studies have reported conventional or quantitative PCR-based assays for the detection of C. botulinum genes, our procedure's high-throughput capability and its portability allows most laboratories to quickly assess the possible presence of BoNTs either in food processing samples or in suspected cases of botulism. Thus, this assay provides rapid and specific detection of BoNT and toxin complex genes and would enable the targeting of appropriate therapeutics to infected individuals in a timely manner.
Clostridium botulinum, an obligate anaerobic spore-forming bacterium, produces botulinum neurotoxin (BoNT), the most potent toxin known [1-3]. BoNT is classified as a Category A biothreat agent by the Centers for Disease Control and Prevention (CDC) because of its lethality and ease of production, transport and dissemination [4,5]. In addition, BoNT poses several threats to the public health: first, the possibility of foodborne botulism represents a major potential health hazard that requires continual monitoring by the food industry. Second, infant botulism has been the most common form of human botulism in the United States for more than 20 years and hospitalizes approximately 80-100 U.S. infants annually [6]. Third, cases of wound botulism due to intravenous drug use continue to increase [7,8].
Botulism toxicity results from one of seven serologically distinct neurotoxins (types A-G) that cause a severe neuroparalytic disease characterized by descending flaccid paralysis [9]. Rarely, unique strains of C. butyricum and C. baratii may also cause human botulism through production and release of BoNT/E and F, respectively [10,11]. The toxin acts by binding to peripheral cholinergic nerve endings and inhibiting release of acetylcholine at the neuromuscular junction. A part of the toxin is a zinc-dependent protease that cleaves target substrate proteins (SNAREs), located either on the plasma membrane or the synaptic vesicle, thereby preventing their binding, fusion and release of neurotransmitter. BoNTs cleave specific amino acids on the target proteins of the SNARE complex. BoNT/A and BoNT/E act on SNAP-25, while BoNT/C targets syntaxin as well as SNAP-25. The remaining toxin types (BoNT/B, BoNT/D, BoNT/E and BoNT/F) all act on synaptobrevin, but at different cleavage sites [12-15].
The potential severity and lethality of the disease warrants sensitive and specific detection and serotyping of toxin and its typing to enable correct administration of serotype-specific antitoxin in a timely manner. Although treatment with Human Botulism Immune Globulin (BabyBIG®) or equine antitoxin is based on clinical findings and should be instituted as rapidly as possible [5,16,17], definitive microbiological diagnosis may take several days or even longer. This extended time to diagnosis occurs because detection of the bacterium and its toxin relies on toxicity assessment in mice (the mouse protection bioassay) and lengthy culture assays, which, while sensitive and specific, may be time-consuming and difficult [18,19]. Moreover, the availability of the mouse protection bioassay is limited due to lack of animal facilities and reagent constraints.
A readily available rapid diagnostic test would be valuable for public health and medical management of foodborne, infant, wound, or bioterrorist botulism outbreaks. Quick, accurate diagnosis would enable the limited supply of equine or human antitoxin to be directed to affected patients, thereby allowing exposed but unaffected individuals to be reassured and spared unnecessary treatment with an equine serum product. A high-throughput assay would also be beneficial to the food industry, where the use of large quantities of mice is impractical.
Several studies have described PCR-based assays that detect the various serotypes of BoNT genes [20-26]. With the advent of quantitative PCR (qPCR), further studies have reported assays that detect the toxin types (A, B, E and F) generally implicated in human illness and food contamination [27-31]. However, comprehensive sequence analysis shows a high level of genetic variability within the toxin types that enables differentiation of toxin types into subtypes [32,33]. Thus, existing assays may not reliably detect all known subtype variants within each botulinum toxin type.
For these reasons we have developed a novel two-step PCR-based assay that can detect both BoNT and other gene sequences located within the toxin gene complex. It is known that C. botulinum DNA is readily attracted to botulinum neurotoxins, necessitating the use of various treatments for the removal of nucleic acids during toxin purification [34-37]. These DNA sequences may be found even in highly purified protein preparations of the toxin and are therefore a reliable surrogate for the presence of BoNT, enabling rapid detection without using mice. As antitoxin doses are administered based on the serotype of toxin and clinical symptoms and not on the amount of active toxin present in the sample, the assay described here will provide the critical information needed for clinicians to treat affected patients. The first step in this procedure is a universal electrophoresis-based PCR that detects the presence of the C. botulinum nontoxin-nonhemagglutinin (NTNH) gene, a highly conserved toxin complex gene that is found in all C. botulinum toxin types and subtypes that has been found in all BoNT-producing C. botulinum gene sequences examined to date [32,38]. Thus, samples that contain BoNT can be identified irrespective of serotype, thereby providing comprehensive but not type-specific detection. A similar independent assay to detect NTNH has recently been reported by Rafael and Andreadis [38]. The second step of the assay uses qPCR to determine quantitatively the specific BoNT toxin type by using seven different degenerate primer/probe pairs, one for each of the seven A-G toxin serotypes. These assays successfully detected toxin genes from 22 of the 26 known toxin subtypes.
Universal detection of the C. botulinum toxin complex gene NTNH
Figure Figure1A1A shows the C. botulinum neurotoxin complex gene organization for each type [39,40] and the primers designed for the nontoxin-nonhemagglutinin gene (NTNH) (Figure (Figure1B),1B), which is present in all C. botulinum types directly upstream from the neurotoxin gene in BoNT toxin gene clusters. The primers target an area that is highly conserved between C. botulinum types A-G. Degenerate primers were designed to accommodate any base discrepancy in the target area.
Figure 1
Figure 1
Selection and design of universal PCR primers. (A) Diagram of C. botulinum neurotoxin gene (BoNT) organization (adapted from Chen et al. 2007) [39]. (B) Non-toxin non-hemagglutinin gene (NTNH) primers targeting a highly conserved area directly upstream (more ...)
We tested these primers with DNA purified from C. botulinum cultures of each toxin type and also included control genomic and plasmid DNA from samples of E. coli bacterial colonies (DH5α) as well as crude lysate from human peripheral blood mononuclear cells. A specific NTNH product of 101 base pairs was detected in each lane containing clostridial DNA representing all toxin serotypes as well as BoNT-producing C. butyricum and C. baratii isolates, but no band was detected in any of the controls.
We also confirmed that detection of the NTNH gene was specific to BoNT-producing clostridial species. Table Table11 shows the results of the universal PCR performed with DNA purified from clostridial species harbouring the BoNT gene and those lacking these genes. A strong PCR product was detected from all samples that expressed detectable levels of BoNTs, but not from any clostridial strain that did not produce BoNTs.
Table 1
Table 1
NTNH gene detection on C. botulinum and other clostridial strains
We next confirmed the robustness of NTNH detection both on food samples that were spiked with purified serotype-specific C. botulinum DNA and on crude toxin preparations. Canned vegetables and canned meat were spiked with 100 μL of purified DNA at dilutions down to 1 genomic copy of type-specific BoNT DNA in 100 μL. DNA was extracted from spiked samples as described in the methods section. Only samples that had been spiked with clostridial DNA from neurotoxin-containing strains tested positive for NTNH (data not shown). As with the food samples, DNA was extracted from crude toxin-containing cultures and tested for the presence of NTNH. All of the purified DNA samples and most of the crude culture supernatant samples examined were positive for NTNH (Table (Table1).1). The lack of amplification from some of the crude culture supernatants may be due to lack of DNA extraction resulting in the presence of proteinaceous PCR inhibitors.
In addition to spiking food, we also spiked healthy infant stool with varying concentrations of BoNT serotype-specific C. botulinum DNA as described in the materials and methods. We detected a positive PCR result in all samples of stool spiked with BoNT DNA to an amount as low as an equivalent of 10 genomic copies. In the sample spiked with BoNT A at an equivalent of 1 genomic copy, we obtained a weak positive PCR result. Additionally, we tested DNA extracted from a clinical sample from a recent case of infant botulism, diagnosed by the mouse protection bioassay, and clearly detected presence of the NTNH gene (Table (Table22).
Table 2
Table 2
NTNH PCR detection in spiked healthy infant stool and a clinical infant botulism sample
Quantitative type-specific detection of C. botulinum
We designed primers and probes specific to each toxin type (A-G). Each set targets portions of the light chain of the neurotoxin gene in areas conserved within each subtype yet unique to each toxin type such that no cross-reactivity should occur. Any base differences between strains were accounted for by incorporation of degenerate bases (Table (Table3).3). As validation, Figure Figure22 shows results of the type-specific qPCR performed on the plasmid standards corresponding to each C. botulinum. Not only was each primer/probe set able to detect its C. botulinum type toxin gene sequence sensitively and specifically, there was also no cross-reactivity of any primer/probe set with a toxin gene sequence from a different C. botulinum type.
Table 3
Table 3
Primer and probe sets for each serotype used in quantitative PCR
Figure 2
Figure 2
qPCR validation of plasmid standards. Each standard dilution tested against type-specific primers and probes and cross-checked with primers and probes specific to all remaining types. Five ten-fold serial dilutions tested with each appropriate primer (more ...)
Figure Figure33 shows quantitative type-specific amplification of DNA purified from laboratory-cultured samples of C. botulinum representing all toxin types A-G. Each primer/probe set amplified only that DNA of the specific toxin gene type with no amplification of toxin gene sequences of a differing type. As confirmation of our assay, we diluted purified DNA from C. botulinum cultures taking into account genomic size and concentration of the DNA preparation. We made 5 ten-fold dilutions representing 105 to one genomic copies of BoNT and tested six replicate reactions per assay. Figure Figure33 (table) shows that the sensitivity of detection is consistently as low as 10 gene copies per reaction. Using our plasmid standards, actual values consistently showed accurate target gene copy numbers within each dilution and were reproducible in each replicate reaction. We were able to detect 1 copy of the BoNT gene in several toxin samples, but the overall detection level of our assay was reliably as few as 10 copies of neurotoxin gene.
Figure 3
Figure 3
qPCR detection of type-specific neurotoxin DNA. Each toxin type DNA amplified with type-specific primers and probes. Assay sensitivity is shown in the table. Each toxin type DNA was amplified with its cognate primer and probe set. The DNA was diluted (more ...)
To confirm the specificity of the assay, we further extracted DNA from pure laboratory-cultures from twenty-nine C. botulinum strains representing twenty-two different toxin subtypes. Amplification occurred only when DNA from a particular BoNT serotype was paired with its type-specific primer/probe set, and there was no cross-reactivity between primer/probe sets of one serotype and toxin genes of a different serotype (Table (Table4).4). Importantly, strains known to produce or contain the genes for two toxin serotypes were successfully confirmed as such by the assay (Figure (Figure44).
Table 4
Table 4
Cross reactivity and specificity of primers and probes with all subtypes of C. botulinum Subtype Specific Primer and Probe set Used in Real Time PCR
Figure 4
Figure 4
Detection of silent genes in dual BoNT containing strains of C. botulinum. Shown are amplification plots of three strains of C. botulinum that contain silent genes: CDC1436 A2b (A), strain 657 Ba4 (B), and strain An436 Bf (C). Copy numbers and the indicated (more ...)
We then tested DNA-spiked food samples and crude culture supernatants for the presence of serotype-specific BoNT genes using the above assays. In spiked food samples, we were able to detect type-specific BoNT DNA down to at least three genomic copies of BoNT DNA in each sample (Figure (Figure5A5A and and5B).5B). To determine relative levels of detections, we tested the four major causes of foodborne botulism, BoNT A, B, E, and F within crude toxin supernatants. Positive PCR signals were seen with sample dilutions containing toxin concentrations of 0.000018 LD50 BoNT/A per ml and 0.00385 LD50 BoNT/B toxin per ml. The level of detection is greater than 50,000 times more sensitive than the mouse bioassay for BoNT/A and greater than 250 times more sensitive than the mouse bioassay for BoNT/B in equivalent samples. Positive PCR signals were observed with sample dilutions equal to 1LD50 in BoNT/E toxin/mL and 0.007 LD50 BoNT/F toxin/mL. Thus the level of detection for BoNT/E and BoNT/F matched or was 1000 times more sensitive than the mouse protection bioassay, respectively (Table (Table55).
Figure 5
Figure 5
qPCR detection of type-specific BoNT DNA in food samples spiked with purified C. botulinum DNA. Canned green beans or corned beef was spiked with ten-fold dilutions of purified type-specific BoNT DNA. Samples were processed and DNA extracted from each (more ...)
Table 5
Table 5
Detection limits of BoNT DNA in crude toxin supernatants
Next, we did comparative testing of crude culture supernatants (without DNA extraction) against purified DNA preparations from the same strains. As the crude culture supernatants contained botulinum neurotoxins, they were tested at an independent location that is registered for the use of botulinum neurotoxins using alternative equipment (the Roche Light Cycler versus the ABI 7700 for the purified DNA preparations). All 23 BoNT-containing samples tested positive for the appropriate toxin subtype, including three samples containing multiple toxin serotypes (A2b, Ba4, and Bf). In addition, the mosaic C/D and D/C strains had positive PCR signals for both serotype C and D, confirming the existence of both BoNT/C and/D gene sequences in these strains. The results, shown in Table Table6,6, indicate that this assay is equally effective at detecting and identifying BoNT genes regardless of the sample (crude culture supernatants or purified DNA preparations) or the equipment used.
Table 6
Table 6
Detection of BoNT DNA from purified DNA of bacterial cultures or extracted DNA from crude toxin supernatants
With the same DNA preparations described in the previous section from healthy infant stool spiked with C. botulinum DNA, we were able to detect type-specific BoNT DNA reliably within all samples spiked with BoNT DNA at the equivalent of 10,000 genomic copies. The stool sample from the confirmed case of infant botulism yielded a positive result with 1650 BoNT/A specific gene copies detected in 5 μL of DNA extracted from the stool sample (Table (Table7).7). This confirms the result that had been obtained in the mouse protection bioassay that had been performed for clinical diagnosis.
Table 7
Table 7
BoNT DNA detection in spiked healthy infant stool and botulism clinical samples
The spectre of bioterrorist use of botulinum toxin presents a new and real danger to public health [4,41], and in such an event a sensitive, specific and rapid diagnostic assay to detect the presence of the bacterium and/or its toxin will be needed. In addition, the possibility of botulinum toxin contamination of manufactured food requires constant monitoring. Indeed, over 90 different food products have been recalled in 2007 due to botulinum toxin contamination http://www.cdc.gov/botulism/botulism.htm. The current gold-standard assay, the mouse protection bioassay, is impractical in situations needing high-throughput analysis of multiple samples possibly at multiple geographical locations. In 2003 the National Institute of Allergy and Infectious Disease (NIAID) issued recommendations for new assays needed to detect botulism (NIAID Expert Panel on Botulism Diagnostics, Bethesda Maryland, May 2003). These recommendations stated that any new assay should be "universal", should be able to detect variants of all toxin types, should be type-specific to determine proper antitoxin treatment, and should be sensitive and quantitative to determine risk assessment.
Various methods that have been reported to address these requirements include immunological assays such as ELISA, ECL western blotting and Immuno-PCR, enzymatic assays such as EndoPEP assays and molecular techniques such as PCR [42-47]. The assays developed thus far offer a more rapid means of diagnosing botulism, but each also has limitations in such areas as sample throughput, cost, inability to distinguish toxin types, ease of use and false negative results [18,48].
PCR is a valuable methodology because it is sensitive, specific, cost-effective, portable, automatable, and high-throughput. However, PCR methods have certain limitations, such as the inability to distinguish between biologically active toxin genes and silent toxin genes in the bacterium [18]. While this is an important limitation as it is the protein toxin rather than the DNA encoding it that poses the threat, this is a rare occurrence since complete loss of toxicity in C. botulinum strains is usually accompanied by loss of phage or plasmids that contain toxin complex genes (personal observations of the co-authors) [49-51]. However, the consistent presence of C. botulinum DNA in even highly purified toxin preparations can serve as a surrogate marker and indicate the presence of toxin when C. botulinum contamination is suspected (T. Smith, unpublished data). Several different PCR methods have been reported, ranging from conventional electrophoresis-based PCR, including multiplex PCR, to real-time PCR and probe hybridization [20,23,27,28,38,48,52,53]. Each PCR-based method is reportedly faster and cheaper than the standard mouse protection bioassay [23]. However, most PCR assays detect a narrow range of toxin types, notably A, B, E and/or F, and do not consider the known genetic variation (subtypes) within each particular toxin type [32,33,54,55]. Botulinum neurotoxins, and their genes, exhibit an extreme amount of variability. Currently, there have been over 26 toxin subtypes identified. These toxin subtypes vary by ~1-32% at the amino acid level and their genes vary by approximately the same percentage at the nucleotide level. Despite this variability, we have been able to successfully detect and correctly identify the serotypes from samples representing 22 of these toxin subtypes.
In our study, we also use PCR technology to detect BoNT DNA in samples attempting to match the mouse protection bioassay in sensitivity and specificity. Our results show that we do surpass the sensitivity and specificity of the mouse protection bioassay in purified DNA when parallel samples of known toxicity and/or BoNT serotype are tested.
We detect BoNT DNA in samples reliably down to ten genomic copies in all strains of each subtype tested. In addition, our assay identified both toxins associated with our bivalent strains, while initial testing using the mouse bioassay only identified the predominant toxin in each case. The PCR assay also differentiated mosaic C/D and D/C strains from parental C and D strains; other methodologies are unable to differentiate these subtypes. With respect to the lower sensitivity of BoNT E detection, the data suggest that the initial genomic load of BoNT E DNA was lower than that of other subtypes. Based on the sensitivity of the assay presented here, BoNT E DNA of the same initial genomic load as the other subtypes tested will exhibit the same sensitivity surpassing the mouse protection bioassay.
Based on previous work to detect the presence of microbial 16S ribosomal DNA in human plasma samples during human immunodeficiency virus (HIV) infection to determine microbial translocation, we were able to determine the presence of bacterial DNA in human plasma using similar extraction and quantitative PCR techniques as described here [56]. Clearly, when dealing with clinical samples such as stool in which PCR inhibitors may present a challenge in detection of the BoNT DNA genes, there was a decrease in the detection limit of spiked healthy infant stool sample. However, in testing a confirmed infant botulism case in which the DNA tested was obtained from stool, we were readily able to determine the presence of the NTNH gene as well as its type and concentration.
The two-step PCR assay described here fulfils the criteria recommended by the NIAID expert panel [57]. The first step, universal PCR detects the NTNH toxin complex gene that is conserved in all C. botulinum strains. The NTNH gene can be used as a high-throughput screening tool to determine those samples or individuals contaminated or infected with C. botulinum regardless of the type. The second step qPCR is used to determine the specific toxin type present and to estimate the extent of contamination by determining the gene load in each sample. A measure of the BoNT gene load may be helpful to the food industry to detect the presence and extent of contamination. Although the BoNT gene load may not predict the severity of illness, a fast, sensitive, and specific toxin detection assay will enable prompt administration of appropriate antitoxin therapy and assessment of the public health risk from suspect foods. With this assay's high-throughput capability and its portability, any laboratory may use it to assess quickly the possible presence of BoNTs either in food processing samples or in suspected cases of botulism. Thus, this assay provides rapid and specific detection of BoNT and toxin complex genes and would enable the targeting of appropriate therapeutic agents (eg: BabyBig® or equine antitoxin) to infected individuals in a timely manner.
Bacterial strains and DNA purification
All strains tested within this report are listed in Table Table8.8. DNA used in each PCR test was extracted from bacterial cultures as previously described [32]. Briefly, TPGY broth (Difco, Becton Dickinson and Co., Franklin Lakes, NJ) was inoculated with isolated C. botulinum bacterial colonies from each type and incubated anaerobically for 48 hours at 35°C for Group I strains and Group II strains were grown at 30 C°C followed by low speed centrifugation harvesting. The pellets were resuspended in TE and quickly frozen in a dry ice/ethanol bath at -70°C for three successive cycles followed by melting at 65°C. Sodium dodecylsulfate (SDS) and Proteinase K (10 mg/ml) were added, mixed, and incubated at 42°C for 1 hour. After incubation, 5 M NaCl solution and 10% (w/v) CTAB (cetyl trimethyl ammonium bromide) solution were added, mixed thoroughly and incubated at 65°C for 10 minutes. Following this incubation, three organic extractions of the mixture were performed using phenol/chloroform/isoamyl alcohol. DNA concentration was measured by spectrophotometry and diluted to a concentration of 25 μg/mL.
Table 8
Table 8
Bacterial strains tested in PCR
Crude Toxin Supernatant Preparation
Isolated colonies from an egg yolk or blood agar plate that had been incubated for 48 hours in a gas pack jar were inoculated in ten mL of TPGY broth, (5% Trypticase, 0.5% Bacto Peptone, 2% Yeast extract, 0.4% glucose and 0.2% Cystene). The TPGY broth was then incubated for 5 days at 35°C for proteolytic cultures and 30°C for non-proteolytic cultures in a gas pack jar. Samples were then centrifuged at 4000 rpm for 15 minutes and supernatant was filtered through a 0.22 μm membrane filter. Aliquots were made and stored at -70°C until needed. Sample sterility was tested on blood agar plates that were incubated for 48 hrs then checked for growth.
DNA extraction from spiked food, healthy infant stool, crude toxin samples and infant botulism clinical sample
Canned vegetables and meat from a local market and stool from a healthy infant were separated into aliquots of 200 mg amounts of material. Each solid aliquot was homogenized using a mortar and pestle into a paste. 100 μL of purified DNA from specific C. botulinum strains was added to the food or stool paste at dilutions ranging from 105 to 10 genomic copies. DNA from each sample was then extracted using Qiagen's QiAMP DNA stool mini kit (Qiagen, Valencia CA) using manufacturer's recommendations with one modification. Each sample was bound to the column provided in the kit and washed twice before proceeding to further steps to ensure elimination of any protein debris that may interfere with subsequent PCR analysis. For crude toxin supernatants, DNA was extracted from 200 μL of crude supernatant using the QiAmp DNA stool mini kit as described above. For spiked food, healthy infant stool samples and crude supernatants, extracted DNA was eluted in 50 μL of elution buffer and immediately tested for presence of either NTNH or type-specific BoNT. NTNH assays were done on DNA extracted from crude culture supernatants, as outlined above. The BoNT serotype-specific assays were done on crude culture supernatants with no further extraction or processing. Infant stool DNA from a clinical sample was extracted with the MagNA Pure compact instrument and Nucleic Acid Isolation Kit I (Roche Applied Science) according to the manufacturer instructions.
Universal PCR primer designed for NTNH
Sequences used to design a set of universal PCR primers were obtained from Genbank. All sequences were aligned with MegAlign (DNASTAR, Lasergene, Inc.). Both Primer Express (Applied Biosystems, Foster City, CA) and Primer3 (http://frodo.wi.mit.edu/primer3/), were used to design a pair of degenerate primers that included base differences to detect all known NTNH gene variants. Primer sequences are designated in Figure Figure11.
Universal PCR for detection of NTNH of all C. botulinum types
Purified DNA from C. botulinum, E. coli bacterial DNA (pUC19 plasmid DNA) or crude lysate from human leukocytes were used in the universal PCR. PCR conditions were as follows: 95°C for 5 minutes, then 35 cycles of 95°C for 15 seconds and 57°C for 1 minute. PCR reaction mixture contained PCR Buffer, 3.5 uM MgCl2, 200 nM dNTP, 1 uM forward or reverse primer, 0.25 U Taq Polymerase (Invitrogen Corp, Carlsbad, CA). 5 μL of DNA (0.25 ng/uL) was used in each 25 μL PCR reaction. PCR products were run on a 2.5% agarose gel to separate the product from any non-specific amplification and visualized for 101 bp bands by UV illumination.
Toxin type-specific qPCR primer and probe design
Neurotoxin gene sequences, obtained both from Genbank and from sequences provided by Biosciences Division, Los Alamos National Laboratories, were aligned and degenerate primer/probe sets were designed using software packages as above for each toxin type. Each degenerate primer/probe set include all known base differences within each toxin type.
Generation of qPCR standards for each C. botulinum toxin type-specific assay
Seven samples of purified C. botulinum DNA, one for each toxin type, were used in the generation of plasmid DNA standards for qPCR. Briefly, primers designed specifically for each toxin type were used to amplify a region of the toxin gene containing the degenerate primer/probe set target sequences. The PCR conditions were as follows: 95°C for 5 minutes, then 35 cycles of 95°C for 15 seconds and 60°C for 1 minute. PCR reaction mixture contained PCR Buffer, 3.5 uM MgCl2, 200 nM dNTPs, 500 nM forward or reverse primer, 0.25 U Taq Polymerase (Invitrogen). 5 μL of DNA (0.25 ng/uL) was used in each 25 μL PCR reaction. PCR products were visualized by UV on a 1.5% agarose gel. Corresponding specific products were gel purified and ligated into pGEM T-easy vector (Promega Corp., Madison, WI). Ligations were transformed into DH5α E.coli bacteria using α-complementation to determine positive colonies. Positive colonies were grown in overnight cultures, plasmid DNA was purified and sequenced for determination of correct subtype insert sequence. DNA was quantified by UV spectrophotometry and serial dilutions of plasmid standard were made from 106 to 102 target molecules/5 μL.
qPCR for BoNT Type-Specific Detection
The qPCR assay consisted of seven separate reactions, each specific for one of the seven neurotoxin gene types. For absolute quantification, template standards for each of the neurotoxin gene types were run alongside the DNA samples for each of the seven qPCRs. qPCR conditions were as follows: 95°C for 5 minutes, then 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. PCR reaction mixture contained PCR Buffer, 3.5 uM MgCl2, 200 nM dNTPs, 500 nM forward or reverse primer, 200 nM Fam/BHQ1-labeled probe, 3 nM BD636 reference dye, 0.25 U Taq Polymerase (Invitrogen Corp, Carlsbad, CA). 5 μL of purified DNA or plasmid standard was used in each 25 μL PCR reaction. Based on cycle of threshold (Ct) values with known copy numbers of plasmid in each reaction, a standard curve is generated that will be used to calculate the values of unknown samples.
Authors' contributions
BH designed all primers and probes and optimized and performed PCRs based on purified DNA or spiked food samples as well as clinical samples. JS performed all PCR assays on crude toxin preparations. TS provided DNA and crude toxin preparations for PCR testing. DD and SA conceived the study and guided its design. All authors contributed to interpretation of data and preparation of this manuscript. All authors have read and approve of this final manuscript.
Acknowledgements
We would like to thank Dr. David Kulesh from USAMRIID for his expert technical advice and the use of equipment. We would also like to thank Dr. Nir Dover for extracting and providing fecal DNA from the California patient with infant botulism. We also thank Alma Boritz for contributing a healthy infant stool sample.
The opinions, interpretations and recommendations are those of the author and are not necessarily those of the US Army.
  • Montecucco C. Clostridial neurotoxins: the molecular pathogenesis of tetanus and botulism. Current Topics of Microbial immunology. 1995;195:1–278.
  • Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46(1):86–94. [PMC free article] [PubMed]
  • Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274–279. doi: 10.1016/j.coph.2004.12.006. [PubMed] [Cross Ref]
  • Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M. et al. Botulinum toxin as a biological weapon: medical and public health management. Jama. 2001;285(8):1059–1070. doi: 10.1001/jama.285.8.1059. [PubMed] [Cross Ref]
  • Centers for Disease Control C. Centers for Disease Control and Prevention: Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Atlanta, GA. Centers for Disease Control and Prevention; 1998.
  • Koepke RJS, Arnon SS. Global Occurrence of Infant Botulism, 1976-2006. Pediatrics. 2008. in press . [PubMed]
  • Akbulut D, Dennis J, Gent M, Grant KA, Hope V, Ohai C, McLauchlin J, Mithani V, Mpamugo O, Ncube F. et al. Wound botulism in injectors of drugs: upsurge in cases in England during 2004. Euro Surveill. 2005;10(9):172–174. [PubMed]
  • Artin I, Bjorkman P, Cronqvist J, Radstrom P, Holst E. First case of type E wound botulism diagnosed using real-time PCR. J Clin Microbiol. 2007;45(11):3589–3594. doi: 10.1128/JCM.01192-07. [PMC free article] [PubMed] [Cross Ref]
  • Sobel J. Botulism. Clin Infect Dis. 2005;41(8):1167–1173. doi: 10.1086/444507. [PubMed] [Cross Ref]
  • Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21(4):654–655. [PMC free article] [PubMed]
  • McCroskey LM, Hatheway CL, Fenicia L, Pasolini B, Aureli P. Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol. 1986;23(1):201–202. [PMC free article] [PubMed]
  • Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl 1):S16–24. doi: 10.1046/j.1526-4610.43.7s.4.x. [PubMed] [Cross Ref]
  • Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359(6398):832–835. doi: 10.1038/359832a0. [PubMed] [Cross Ref]
  • Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992;267(33):23479–23483. [PubMed]
  • Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 1996;35(8):2630–2636. doi: 10.1021/bi9519009. [PubMed] [Cross Ref]
  • Arnon SS. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Pediatrics. 2007;119(4):785–789. doi: 10.1542/peds.2006-0646. [PubMed] [Cross Ref]
  • Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–471. doi: 10.1056/NEJMoa051926. [PubMed] [Cross Ref]
  • Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19(2):298–314. doi: 10.1128/CMR.19.2.298-314.2006. [PMC free article] [PubMed] [Cross Ref]
  • Solomon HM, Lilly T. , JrIn: Chapter 17 - Clostridium botulinum. RI M, editor. Center for Food Safety and Applied Nutrition, Food and Drug Administration; 2001. Bacteriological Analytical Manual online - Clostridium botulinum.
  • Campbell KD, Collins MD, East AK. Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. J Clin Microbiol. 1993;31(9):2255–2262. [PMC free article] [PubMed]
  • Dahlenborg M, Borch E, Radstrom P. Development of a combined selection and enrichment PCR procedure for Clostridium botulinum Types B, E, and F and its use to determine prevalence in fecal samples from slaughtered pigs. Appl Environ Microbiol. 2001;67(10):4781–4788. doi: 10.1128/AEM.67.10.4781-4788.2001. [PMC free article] [PubMed] [Cross Ref]
  • Fach P, Gibert M, Griffais R, Guillou JP, Popoff MR. PCR and gene probe identification of botulinum neurotoxin A-, B-, E-, F-, and G-producing Clostridium spp. and evaluation in food samples. Appl Environ Microbiol. 1995;61(1):389–392. [PMC free article] [PubMed]
  • Lindstrom M, Keto R, Markkula A, Nevas M, Hielm S, Korkeala H. Multiplex PCR assay for detection and identification of Clostridium botulinum types A, B, E, and F in food and fecal material. Appl Environ Microbiol. 2001;67(12):5694–5699. doi: 10.1128/AEM.67.12.5694-5699.2001. [PMC free article] [PubMed] [Cross Ref]
  • McGrath S, Dooley JS, Haylock RW. Quantification of Clostridium botulinum toxin gene expression by competitive reverse transcription-PCR. Appl Environ Microbiol. 2000;66(4):1423–1428. doi: 10.1128/AEM.66.4.1423-1428.2000. [PMC free article] [PubMed] [Cross Ref]
  • Szabo EA, Pemberton JM, Desmarchelier PM. Detection of the genes encoding botulinum neurotoxin types A to E by the polymerase chain reaction. Appl Environ Microbiol. 1993;59(9):3011–3020. [PMC free article] [PubMed]
  • Franciosa G, Hatheway CL, Aureli P. The detection of a deletion in the type B neurotoxin gene of Clostridium botulinum A(B) strains by a two-step PCR. Lett Appl Microbiol. 1998;26(6):442–446. doi: 10.1046/j.1472-765X.1998.00367.x. [PubMed] [Cross Ref]
  • Akbulut D, Grant KA, McLauchlin J. Development and application of Real-Time PCR assays to detect fragments of the Clostridium botulinum types A, B, and E neurotoxin genes for investigation of human foodborne and infant botulism. Foodborne Pathog Dis. 2004;1(4):247–257. doi: 10.1089/fpd.2004.1.247. [PubMed] [Cross Ref]
  • Akbulut D, Grant KA, McLauchlin J. Improvement in laboratory diagnosis of wound botulism and tetanus among injecting illicit-drug users by use of real-time PCR assays for neurotoxin gene fragments. J Clin Microbiol. 2005;43(9):4342–4348. doi: 10.1128/JCM.43.9.4342-4348.2005. [PMC free article] [PubMed] [Cross Ref]
  • Kimura B, Kawasaki S, Nakano H, Fujii T. Rapid, quantitative PCR monitoring of growth of Clostridium botulinum type E in modified-atmosphere-packaged fish. Appl Environ Microbiol. 2001;67(1):206–216. doi: 10.1128/AEM.67.1.206-216.2001. [PMC free article] [PubMed] [Cross Ref]
  • Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70(11):6459–6465. doi: 10.1128/AEM.70.11.6459-6465.2004. [PMC free article] [PubMed] [Cross Ref]
  • Yoon SY, Chung GT, Kang DH, Ryu C, Yoo CK, Seong WK. Application of real-time PCR for quantitative detection of Clostridium botulinum type A toxin gene in food. Microbiol Immunol. 2005;49(6):505–511. [PubMed]
  • Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT. et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007;189(3):818–832. doi: 10.1128/JB.01180-06. [PMC free article] [PubMed] [Cross Ref]
  • Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA. et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005;73(9):5450–5457. doi: 10.1128/IAI.73.9.5450-5457.2005. [PMC free article] [PubMed] [Cross Ref]
  • Kitamura M, Sakaguchi S, Sakaguchi G. Purification and some properties of Clostridium botulinum type-E toxin. Biochim Biophys Acta. 1968;168(2):207–217. [PubMed]
  • Kozaki S, Sakaguchi S, Sakaguchi G. Purification and some properties of progenitor toxins of Clostridium botulinum type B. Infect Immun. 1974;10(4):750–756. [PMC free article] [PubMed]
  • Miyazaki S, Iwasaki M, Sakaguchi G. Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect Immun. 1977;17(2):395–401. [PMC free article] [PubMed]
  • Oishi I, Sakaguchi G. Purification of Clostridium botuliunum type F progenitor toxin. Appl Microbiol. 1974;28(6):923–928. [PMC free article] [PubMed]
  • Raphael BH, Andreadis JD. Real-time PCR detection of the nontoxic nonhemagglutinin gene as a rapid screening method for bacterial isolates harboring the botulinum neurotoxin (A-G) gene complex. J Microbiol Methods. 2007;71(3):343–346. doi: 10.1016/j.mimet.2007.09.016. [PubMed] [Cross Ref]
  • Chen Y, Korkeala H, Aarnikunnas J, Lindstrom M. Sequencing the botulinum neurotoxin gene and related genes in Clostridium botulinum type E strains reveals orfx3 and a novel type E neurotoxin subtype. J Bacteriol. 2007;189(23):8643–8650. doi: 10.1128/JB.00784-07. [PMC free article] [PubMed] [Cross Ref]
  • Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon. 2001;39(11):1703–1722. doi: 10.1016/S0041-0101(01)00157-X. [PubMed] [Cross Ref]
  • Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11–18. doi: 10.1080/10408410590912952. [PubMed] [Cross Ref]
  • Dezfulian M, Bartlett JG. Detection of Clostridium botulinum type A toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals. J Clin Microbiol. 1984;19(5):645–648. [PMC free article] [PubMed]
  • Dezfulian M, Hatheway CL, Yolken RH, Bartlett JG. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type A and type B toxins in stool samples of infants with botulism. J Clin Microbiol. 1984;20(3):379–383. [PMC free article] [PubMed]
  • Ekong TA, McLellan K, Sesardic D. Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J Immunol Methods. 1995;180(2):181–191. doi: 10.1016/0022-1759(94)00313-L. [PubMed] [Cross Ref]
  • Poli MA, Rivera VR, Neal D. Development of sensitive colorimetric capture ELISAs for Clostridium botulinum neurotoxin serotypes E and F. Toxicon. 2002;40(6):797–802. doi: 10.1016/S0041-0101(01)00288-4. [PubMed] [Cross Ref]
  • Rodriguez A, Dezfulian M. Rapid identification of Clostridium botulinum and botulinal toxin in food. Folia Microbiol (Praha) 1997;42(2):149–151. doi: 10.1007/BF02898726. [PubMed] [Cross Ref]
  • Wu HC, Huang YL, Lai SC, Huang YY, Shaio MF. Detection of Clostridium botulinum neurotoxin type A using immuno-PCR. Lett Appl Microbiol. 2001;32(5):321–325. doi: 10.1046/j.1472-765X.2001.00909.x. [PubMed] [Cross Ref]
  • Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of Clostridium botulinum types A, B and E in food, soil and infant faeces. J Appl Bacteriol. 1994;76(6):539–545. [PubMed]
  • Eklund MW, Poysky FT, Reed SM, Smith CA. Bacteriophage and the toxigenicity of Clostridium botulinum type C. Science. 1971;172(982):480–482. doi: 10.1126/science.172.3982.480. [PubMed] [Cross Ref]
  • Eklund MW, Poysky FT, Reed SM. Bacteriophage and the toxigenicity of Clostridium botulinum type D. Nat New Biol. 1972;235(53):16–17. [PubMed]
  • Eklund MW, Poysky FT, Mseitif LM, Strom MS. Evidence for plasmid-mediated toxin and bacteriocin production in Clostridium botulinum type G. Appl Environ Microbiol. 1988;54(6):1405–1408. [PMC free article] [PubMed]
  • Aranda E, Rodriguez MM, Asensio MA, Cordoba JJ. Detection of Clostridium botulinum types A, B, E and F in foods by PCR and DNA probe. Lett Appl Microbiol. 1997;25(3):186–190. doi: 10.1046/j.1472-765X.1997.00204.x. [PubMed] [Cross Ref]
  • Gauthier M, Cadieux B, Austin JW, Blais BW. Cloth-based hybridization array system for the detection of Clostridium botulinum type A, B, E, and F neurotoxin genes. J Food Prot. 2005;68(7):1477–1483. [PubMed]
  • Demarchi J, Mourgues C, Orio J, Prevot AR. [Existence of type D botulism in man.] Bull Acad Natl Med. 1958;142(21-22):580–582. [PubMed]
  • Oguma K, Yokota K, Hayashi S, Takeshi K, Kumagai M, Itoh N, Tachi N, Chiba S. Infant botulism due to Clostridium botulinum type C toxin. Lancet. 1990;336(8728):1449–1450. doi: 10.1016/0140-6736(90)93157-K. [PubMed] [Cross Ref]
  • Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–1185. doi: 10.1086/597476. [PMC free article] [PubMed] [Cross Ref]
  • NIAID. NIAD Expert Panel on Botulism Diagnostics: May 23, 2003 2003; Bethesda, Maryland. NIAID; 2003. NIAID Expert Panel on Botulism Diagnostics; pp. 1–14.
Articles from BMC Microbiology are provided here courtesy of
BioMed Central